SynAct Pharma AB (OSTO:SYNACT) E10: kr-7.63 (As of Mar. 2026)


OSTO:SYNACT SynAct Pharma AB OSTO:SYNACT
18 GF Score
Price kr15.44
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB E10?

SynAct Pharma AB OSTO:SYNACT +0.92% 18 E10 is kr-7.63 as of Mar. 2026. GuruFocus rates OSTO:SYNACT with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

SynAct Pharma AB's adjusted earnings per share data for the three months ended in Mar. 2026 was kr-48.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr-7.63 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-29), SynAct Pharma AB's current stock price is kr15.44. SynAct Pharma AB's E10 for the quarter that ended in Mar. 2026 was kr-7.63. SynAct Pharma AB's Shiller PE Ratio of today is .


SynAct Pharma AB  (OSTO:SYNACT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


SynAct Pharma AB E10 Related Terms


SynAct Pharma AB E10 Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB E10 Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SynAct Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -7.63

OSTO:SYNACT vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, SynAct Pharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynAct Pharma AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's Shiller PE Ratio falls into.


OSTO:SYNACT
18GF Score
SynAct Pharma AB OSTO:SYNACT
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SynAct Pharma AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-48/133.3862*133.3862
=-48.000

Current CPI (Mar. 2026) = 133.3862.

SynAct Pharma AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.776 101.019 -1.025
201609 -0.161 101.138 -0.212
201612 -0.786 102.022 -1.028
201703 -0.265 102.022 -0.346
201706 -0.326 102.752 -0.423
201709 -0.148 103.279 -0.191
201712 -0.454 103.793 -0.583
201803 -0.247 103.962 -0.317
201806 -0.582 104.875 -0.740
201809 -0.444 105.679 -0.560
201812 -0.384 105.912 -0.484
201903 -0.266 105.886 -0.335
201906 -0.424 106.742 -0.530
201909 -0.207 107.214 -0.258
201912 -0.734 107.766 -0.909
202003 -0.138 106.563 -0.173
202006 -0.513 107.498 -0.637
202009 -0.858 107.635 -1.063
202012 -0.347 108.296 -0.427
202103 -0.454 108.360 -0.559
202106 -0.505 108.928 -0.618
202109 -0.694 110.338 -0.839
202112 -1.001 112.486 -1.187
202203 -0.760 114.825 -0.883
202206 -0.902 118.384 -1.016
202209 -0.832 122.296 -0.907
202212 -1.070 126.365 -1.129
202303 -1.576 127.042 -1.655
202306 -1.358 129.407 -1.400
202309 -0.991 130.224 -1.015
202312 -2.557 131.912 -2.586
202403 -0.694 132.205 -0.700
202406 -0.466 132.716 -0.468
202409 -0.495 132.304 -0.499
202412 -0.440 132.987 -0.441
202503 -0.510 132.825 -0.512
202506 -0.560 133.699 -0.559
202509 -0.670 133.482 -0.670
202512 -0.430 133.386 -0.430
202603 -48.000 133.386 -48.000

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of kr-7.63 mean?
SynAct Pharma AB (OSTO:SYNACT) has a E10 of kr-7.63 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on SynAct Pharma AB and its competitors.
Is SynAct Pharma AB's E10 too high?
SynAct Pharma AB's current E10 is kr-7.63. Overall, SynAct Pharma AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's E10 compare to VRTX and REGN?
SynAct Pharma AB's E10 of kr-7.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on SynAct Pharma AB and its competitors. SynAct Pharma AB's current E10 is kr-7.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current E10 of kr-7.63. The current E10 is kr-7.63. SynAct Pharma AB's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current E10 is kr-7.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges 8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
18GF Score

Get the complete analysis for OSTO:SYNACT

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr15.44
Price